Sravanti Rangaraju

Statistics

Publications

Citations

562

H-Index

Active since

2014

Affiliations

Massachusetts General Hospital(Current)

City Of Hope National Medical Center

The University of Texas MD Anderson Cancer Center

University of Alabama at Birmingham

University of Utah

Sravanti Rangaraju is an author at Massachusetts General Hospital specializing in chemotherapy in hematologic malignancies, hematologic malignancy therapy, and medicine.

ORCID

Publications per year

2014–2024

Publications

Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Patrick A. Brown, Bijal Shah, Anjali S. Advani et al. · Journal of the National Comprehensive Cancer Network · 2021 · 241 citations · Full text

Medicine, Oncology, Pediatrics +17

Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease

Alyson Swimm, Cynthia R. Giver, Zachariah DeFilipp et al. · Blood · 2018 · 179 citations · Full text

Life Sciences, Immunology, Microbiology +14

Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Bijal Shah, Ryan J. Mattison, Ramzi Abboud et al. · Journal of the National Comprehensive Cancer Network · 2024 · 56 citations

Medicine, Hematology, Oncology +16

Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

Ajay K. Nooka, H. R. M. Johnson, Jonathan L. Kaufman et al. · Biology of Blood and Marrow Transplantation · 2014 · 32 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacology +17

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations

Christian Récher, Jenny O’Nions, Ibrahim Aldoss et al. · Blood · 2024 · 26 citations · Full text

Medicine, Oncology, Pharmacology +11

1–5 of 7